Bristol Myers Squibb appoints Chris Shibutani, M.D., a former Goldman Sachs biotech analyst and practicing anesthesiologist, as EVP and Chief Strategy Officer to guide long-term strategy and partnerships. Meanwhile, the FDA’s oncology advisory committee will review GSK’s proposed relaunch of multiple myeloma drug Blenrep. Separately, FDA Commissioner Martin Makary announces plans for further agency operational consolidation. These developments reflect evolving strategic and regulatory landscapes shaping pharma and biotech sectors.